Payers’ Hands Are Still Tied With Oncology Combination Regimens

Posted by Nicolle Hamilton on May 23, 2019 10:11:35 AM

Lawrence Lee co-wrote this blog post with Nicolle Hamilton.  

The oncology pipeline is rich with potential combination regimens across both liquid and solid tumor types. Several manufacturers are developing or marketing PD-1/PD-L1 checkpoint inhibitors as a “backbone” for their combination regimen portfolio. Although there are only a few currently marketed regimens with multiple targeted agents (such as Opdivo-Yervoy in ovarian cancer, Tafinlar-Mekinist in metastatic melanoma, and several combos in multiple myeloma), combination approaches may become the standard of care for many tumor types. Indeed, these novel-novel approaches can yield compelling clinical outcomes. For example, Opdivo-Yervoy reduced progression risk by 58% vs. Yervoy alone in melanoma.


>
Read More

Preparing for the First Wave: Biosimilars at ASCO 2018

Posted by Max Kuehn on Sep 5, 2018 8:00:00 AM

As always, clinical innovation dominated the conversation at ASCO 2018, but many attendees also made time to attend sessions on value and financial burden, where biosimilars were a frequent topic. With more than 40 biosimilars already approved in the EU, and rituximab, trastuzumab and bevacizumab biosimilars approaching launch in the U.S., biosimilars will play a major role in the future oncology landscape. 


>
Read More

Oncology Experts Pinpoint the Key Drivers and Barriers of Biosimilar Adoption

Posted by ZS Editors on Aug 30, 2017 8:00:00 AM

Biosimilars are beginning to permeate the U.S. oncology market, but the floodgates aren’t exactly open. Despite their promise to expand treatment options and rein in cancer costs, biosimilars continue to face prescriber inexperience and other challenges that affect adoption levels. To execute an effective go-to-market strategy in the evolving cancer landscape, biosimilar manufacturers must contend with increasing competition, overcome patent disputes, and develop education programs for biosimilar-naïve stakeholders. Meanwhile, manufacturers of originator products will need to develop effective defense strategies in anticipation of biosimilar competition


>
Read More

Oncology Pathways: Who Controls the Menu at Healthcare’s ‘Dinner for Three’?

Posted by Paul Darling on Mar 21, 2016 8:00:00 AM

In recent years, payers have made an effort to exert more control over physicians’ treatment decisions, especially in oncology. They’ve created clinical pathways that set out treatment guidelines and use prior authorizations and step therapy to encourage physicians to select payers’ preferred protocols and drugs.


>
Read More